BiotechTube

ADX-2191 + ADX-2191

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Retinitis Pigmentosa

Conditions

Retinitis Pigmentosa

Trial Timeline

Jul 14, 2022 → Jun 23, 2023

NCT ID
NCT05392179

About ADX-2191 + ADX-2191

ADX-2191 + ADX-2191 is a phase 2 stage product being developed by Aldeyra Therapeutics for Retinitis Pigmentosa. The current trial status is completed. This product is registered under clinical trial identifier NCT05392179. Target conditions include Retinitis Pigmentosa.

What happened to similar drugs?

0 of 3 similar drugs in Retinitis Pigmentosa were approved

Approved (0) Terminated (0) Active (3)
🔄Valganciclovir + GanciclovirRochePhase 3
🔄GanciclovirRochePhase 3
🔄ValganciclovirRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05392179Phase 2Completed

Competing Products

20 competing products in Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
39
AGN-151597AbbViePhase 1/2
32
CPK850NovartisPhase 1/2
36
Valganciclovir + GanciclovirRochePhase 3
40
ValganciclovirRochePre-clinical
26
Foscarnet sodium + GanciclovirRochePhase 1
29
GanciclovirRochePhase 1
29
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 2
35
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Zidovudine + Sargramostim + GanciclovirRochePre-clinical
26
Zidovudine + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Interferon beta-1b + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 3
40
ValganciclovirRochePhase 3
36
Cidofovir + ProbenecidGilead SciencesPre-clinical
26